Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.
4-1BB
CD19
T cell
chimeric antigen receptor
immunotherapy
leukemia
lymphoma
preclinical studies
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
15 Mar 2019
15 Mar 2019
Historique:
received:
31
08
2018
accepted:
29
11
2018
entrez:
10
1
2019
pubmed:
10
1
2019
medline:
10
1
2019
Statut:
epublish
Résumé
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells
Identifiants
pubmed: 30623002
doi: 10.1016/j.omtm.2018.11.010
pii: S2329-0501(18)30122-0
pmc: PMC6319086
doi:
Types de publication
Journal Article
Langues
eng
Pagination
134-144Références
Tissue Antigens. 2000 Aug;56(2):117-28
pubmed: 11019911
Am J Pathol. 2001 Sep;159(3):861-73
pubmed: 11549579
Nucleic Acids Res. 2002 Jan 15;30(2):E9
pubmed: 11788735
J Immunol. 2005 Jun 1;174(11):7033-42
pubmed: 15905546
J Immunother. 2009 Feb-Mar;32(2):169-80
pubmed: 19238016
J Clin Invest. 2009 Apr;119(4):964-75
pubmed: 19307726
Mol Ther. 2009 Aug;17(8):1453-64
pubmed: 19384291
J Immunother. 2009 Sep;32(7):689-702
pubmed: 19561539
CSH Protoc. 2008 Mar 01;2008:pdb.prot4977
pubmed: 21356793
Blood. 2011 Nov 3;118(18):4817-28
pubmed: 21849486
Bioprocess Int. 2012 Feb;10(2):32-43
pubmed: 22707919
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958
Annu Rev Med. 2014;65:333-47
pubmed: 24274181
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Cancer Gene Ther. 2015 Mar;22(2):72-8
pubmed: 25613483
Cancer Gene Ther. 2015 Mar;22(2):85-94
pubmed: 25721207
Scand J Immunol. 2015 Oct;82(4):307-19
pubmed: 26099639
J Clin Invest. 2015 Sep;125(9):3392-400
pubmed: 26325036
N Engl J Med. 2015 Sep 10;373(11):1040-7
pubmed: 26352815
Mol Ther Methods Clin Dev. 2016 Apr 13;3:16017
pubmed: 27110581
Blood. 2016 Jun 16;127(24):2980-90
pubmed: 27118452
Mol Ther Oncolytics. 2016 Jun 15;3:16015
pubmed: 27347557
Sci Transl Med. 2016 Sep 7;8(355):355ra116
pubmed: 27605551
Trends Mol Med. 2017 May;23(5):430-450
pubmed: 28416139
Blood. 2017 Nov 23;130(21):2295-2306
pubmed: 28924019
Front Immunol. 2018 Jan 10;8:1956
pubmed: 29375575
J Virol. 1998 Nov;72(11):8463-71
pubmed: 9765382
J Virol. 1998 Dec;72(12):9873-80
pubmed: 9811723